All In Biotech

Drug Trial Radar · NCT07949799

A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION

AN OPEN-LABEL, PARALLEL-GROUP CLINICAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES FOLLOWING A SINGLE DOSE IN PARTICIPANTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT AND PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Dec 17, 2026

Primary completion

Apr 29, 2027

Study completion Jun 1, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function

Conditions

  • Hepatic Impairment

Interventions

  • FXS6837 capsuleDrug

    Mild hepatic impairment, FXS6837 125mg orally once.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:CmaxTime frame: Up to Day 14
  2. Primary PK parameter of FXS6837 in plasma: AUC0-tTime frame: Up to Day 14
  3. Primary PK parameter of FXS6837 in plasma: AUC0-∞Time frame: Up to Day 14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.